Emera Reports 2019 First Quarter Financial Results
Reading Time: 6 minutes
HALIFAX, Nova Scotia–(BUSINESS WIRE)–Today Emera (TSX: EMA) announced financial results for the first quarter
of 2019.
Q1 2019 Highlights:
Reported Net Income
-
Q1 2019 reported net income was $312 million, compared with net income
of $271 million in Q1 2018 -
Q1 2019 reported earnings per common share were $1.32, compared with
$1.17 per common share in Q1 2018
Adjusted Net Income (1)
-
Q1 2019 adjusted net income was $224 million, compared with $202
million in Q1 2018 -
Q1 2019 adjusted earnings per common share were $0.95, compared with
$0.87 in Q1 2018
Cash Flow
-
Operating cash flow, before changes in working capital, decreased by
$26 million to $418 million in Q1 2019, compared with $444 million in
Q1 2018
DRIP Discount
-
Discount offered on the reinvestment of cash dividends under the
dividend reinvestment plan (the “DRIP”) reduced from five per cent to
two per cent
(1) See “Non-GAAP Measures” noted below.
“Our business continued to perform well during the first quarter,
delivering strong financial results while making measurable progress on
our strategic objectives,” said Scott Balfour, President and CEO. “With
the recent close of our New England Gas Generation transaction and the
announced sale of Emera Maine, we are well positioned to focus on our
robust capital investment profile.”
Financial Highlights:
| For the | Three months ended March 31 | |||||
| millions of Canadian dollars (except per share amounts) | 2019 | 2018 | ||||
| Net income attributable to common shareholders | $ | 312 | $ | 271 | ||
| After-tax mark-to-market gain (loss) | 88 | $ | 69 | |||
| Adjusted net income attributable to common shareholders (1)(2) | $ | 224 | $ | 202 | ||
| Earnings per common share – basic | $ | 1.32 | $ | 1.17 | ||
| Adjusted earnings per common share – basic (1)(2) | $ | 0.95 | $ | 0.87 | ||
|
Weighted average shares of common stock outstanding – basic (millions of shares) |
236 | 231 | ||||
(1) See “Non-GAAP Measures” noted below
(2)
Adjusted net income and adjusted earnings per common share exclude the
effect of mark-to-market adjustments
After-tax mark-to-market gains increased $19 million to $88 million in
2019 compared to $69 million in 2018, mainly due to changes in Emera
Energy’s existing positions on gas contracts and a larger reversal of
mark-to-market losses in 2019 compared to 2018, partially offset by
higher amortization of gas transportation assets in 2019.
The weaker Canadian dollar increased earnings by $13 million and
adjusted earnings by $8 million in Q1 2019 compared to Q1 2018.
Consolidated Financial Review:
The following table highlights significant changes in adjusted net
income from 2018 to 2019 in the first quarter.
| For the | Three months ended | ||
| millions of Canadian dollars | March 31 | ||
| Adjusted net income – 2018 (1)(2) | $ | 202 | |
| Gas Utilities and Infrastructure | 14 | ||
| Gain on sale of property in Florida | 10 | ||
| Canadian Electric Utilities | 6 | ||
| Other Variances | (8) | ||
| Adjusted net income – 2019 (1)(2) | $ | 224 |
(1) See “Non-GAAP Measures” noted below
(2)
Excludes the effect of mark-to-market adjustments
Segmented Results:
Effective January 1, 2019, Emera has revised its reportable segments to
align with strategic priorities and internal governance. Emera reports
its results in five operating segments: Florida Electric Utility,
Canadian Electric Utilities, Other Electric Utilities, Gas Utilities and
Infrastructure and Other.
| For the | Three months ended March 31 | |||||
| millions of Canadian dollars (except per share amounts) | 2019 | 2018 | ||||
| Adjusted net income (1) | ||||||
| Florida Electric Utility | $ | 61 | $ | 60 | ||
| Canadian Electric Utilities | 96 | 90 | ||||
| Other Electric Utilities (2) | 16 | 15 | ||||
| Gas Utilities and Infrastructure | 67 | 53 | ||||
| Other (2) | (16) | (16) | ||||
| Adjusted net income (1) | $ | 224 | $ | 202 | ||
| After-tax mark-to-market gain (loss) | 88 | 69 | ||||
| Net income attributable to common shareholders | $ | 312 | $ | 271 | ||
| EPS (basic) | $ | 1.32 | $ | 1.17 | ||
| Adjusted EPS (basic) (1)(2) | $ | 0.95 | $ | 0.87 | ||
(1) See “Non-GAAP Measures” noted below.
(2)
Excludes the effect of mark-to-market adjustments.
Florida Electric Utility’s CAD net income increased by $1 million
to $61 million in Q1 2019, compared to $60 million in Q1 2018. This
increase was due to higher revenues related to the in-service solar
generation projects, lower OM&G due to the timing of generation outages
and a weaker Canadian dollar, partially offset by lower revenues due to
less favourable weather.
Canadian Electric Utilities’ net income increased by $6 million
to $96 million, compared to $90 million in Q1 2019. The increase was due
to higher sales volume due to weather and lower OM&G, primarily a result
of lower storm costs, at Nova Scotia Power Inc.
Other Electric Utilities’ CAD net income, adjusted to exclude
mark-to-market, increased by $1 million to $16 million in Q1 2019,
compared to $15 million in Q1 2018.
Gas Utilities and Infrastructure’s CAD net income increased by
$14 million to $67 million in Q1 2019, compared to $53 million in Q1
2018. This increase was due to favourable weather conditions and the
optimization of pipeline capacity at New Mexico Gas Company, lower
depreciation and amortization at Peoples Gas and customer growth at both
utilities.
Other’s net loss, adjusted to exclude mark-to-market, in Q1 2019
was $16 million, consistent with Q1 2018. Adjusted earnings from Emera
Energy were $52 million, a decrease of $3 million from Q1 2018. Also in
Q1 2019 was a $2 million loss associated with the sales of the New
England Gas Generation portfolio and Bayside and a $10 million gain from
the sale of a property in Florida.
Discount on Reinvested Dividends:
Emera also announced today a change from five per cent to two per cent
of the applicable discount from the average market price for common
shares purchased in connection with the reinvestment of cash dividends
under its DRIP. The revision aligns the Company’s discount rate with
industry peers and offers value for those shareholders electing to
participate in the DRIP. For common shareholders who have elected
participation in the DRIP, reinvestment of their dividends will occur at
the new discount beginning on the next dividend declaration date.
Additional information regarding Emera’s DRIP is available on its
website at www.emera.com.
Non-GAAP Measures
Emera uses financial measures that do not have standardized meaning
under USGAAP and may not be comparable to similar measures presented by
other entities. Emera calculates the non-GAAP measures by adjusting
certain GAAP and non-GAAP measures for specific items the Company
believes are significant, but not reflective of underlying operations in
the period. Refer to the Non-GAAP Financial Measures section of our
Management’s Discussion and Analysis (“MD&A”) for further discussion of
these items.
Forward Looking Information
This news release contains forward-looking information within the
meaning of applicable securities laws. By its nature, forward-looking
information requires Emera to make assumptions and is subject to
inherent risks and uncertainties. These statements reflect Emera
management’s current beliefs and are based on information currently
available to Emera management. There is a risk that predictions,
forecasts, conclusions and projections that constitute forward-looking
information will not prove to be accurate, that Emera’s assumptions may
not be correct and that actual results may differ materially from such
forward-looking information. Additional detailed information about these
assumptions, risks and uncertainties is included in Emera’s securities
regulatory filings, including under the heading “Business Risks and Risk
Management” in Emera’s annual Management’s Discussion and Analysis, and
under the heading “Principal Risks and Uncertainties” in the notes to
Emera’s annual and interim financial statements, which can be found on
SEDAR at www.sedar.com.
Teleconference Call
The company will be hosting a teleconference today, Friday, May 10, 2019
at 9:30 a.m. Atlantic (8:30 a.m. Eastern) to discuss the Q1 2019
financial results.
Analysts and other interested parties in North America are invited to
participate by dialing 1-866-521-4909. International parties are invited
to participate by dialing 1-647-427-2311. Participants should dial in at
least 10 minutes prior to the start of the call. No pass code is
required.
A live and archived audio webcast of the teleconference will be
available on the Company’s website, www.emera.com.
A replay of the teleconference will be available two hours after the
conclusion of the call until June 11, 2019, by dialing 1-800-585-8367
and entering pass code 9045319.
Annual General Meeting
Emera will hold its Annual General Meeting on Wednesday, May 15, 2019 at
2:00 p.m. Atlantic (1:00 p.m. Eastern) at the Halifax Convention Centre,
Argyle Suite, Level 2, 1650 Argyle Street, Halifax, Nova Scotia.
About Emera
Emera Inc. is a geographically diverse energy and services company
headquartered in Halifax, Nova Scotia, with approximately $32 billion in
assets and 2018 revenues of more than $6.5 billion. The company
primarily invests in regulated electricity generation and electricity
and gas transmission and distribution with a strategic focus on
transformation from high carbon to low carbon energy sources. Emera has
investments throughout North America, and in four Caribbean countries.
Emera’s common and preferred shares are listed on the Toronto Stock
Exchange and trade respectively under the symbol EMA, EMA.PR.A,
EMA.PR.B, EMA.PR.C, EMA.PR.E, EMA.PR.F and EMA.PR.H. Depositary receipts
representing common shares of Emera are listed on the Barbados Stock
Exchange under the symbol EMABDR and on The Bahamas International
Securities Exchange under the symbol EMAB. Additional Information can be
accessed at www.emera.com
or at www.sedar.com.
Contacts
Emera Inc.
Investor Relations:
Ken McOnie, VP,
Investor Relations and Treasurer
902-428-6945
[email protected]
Erin
Power, Manager, Investor Relations
902-428-6760
[email protected]
Media:
902-222-2683
[email protected]
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
HERZLIYA, Israel and CALGARY, Alberta, Aug. 29, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has completed its previously announced non-brokered private placement offering of 5,025,725 units of the Company (the “Units”) at a price of C$0.22 per Unit for gross proceeds of C$1,105,659.50 (the “Offering”).
Each Unit is comprised of: (i) one (1) common share in the capital of the Company (each a “Common Share”); and (ii) one (1) common share purchase warrant (each a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$0.32 for a period of four (4) years from the date of issuance.
Innocan intends to use the proceeds of the Offering for working capital and general corporate purposes.
The securities issued to Canadian subscribers in connection with the Offering are subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.
Iris Bincovich, Chief Executive Officer of the Company, stated “we are very pleased with our successful offering. I would like to extend my sincere gratitude to our investors for their unwavering support. We see this as a strong vote of confidence by both existing and new investors which demonstrates investor support of our vision and strategic direction. These new funds will provide us with additional working capital to enable us to capitalize on new opportunities and allow us to advance strongly on our growth plans.”
The Company is also pleased to announce that it has granted an aggregate of 300,000 stock options (each an “Option“) to certain consultants of the Company pursuant to the Company’s stock option plan (the “Plan“). Each Option may be exercised for one (1) common share in the capital of the Company (each, a “Share“) at a price of $0.25 per Share. The Options expire on August 27, 2029.
All Options granted vest in accordance with the following vesting schedule: (i) 1/3rd of the Options vested immediately at grant; (ii) 1/3rd of the Options will vest on February 28, 2025; and (iii) 1/3rd will vest on August 27, 2025; all subject to the terms and conditions of the Plan.
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Logo – https://mma.prnewswire.com/media/2046271/4883982/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options-302234455.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
-
Cannabis2 weeks agoSilly Nice Announces Launch of New 1G 510 Vape Cartridge and 2G All-In-One Vape in New York Dispensaries This September
-
Cannabis2 weeks agoCannabis Cultivation Market – Global Food Additives, Oils, Tinctures, Cannabis Indica, Cannabis Sativa Forecast 2024-2030
-
Cannabis1 week ago
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
-
Cannabis2 weeks ago
Global Hemp Based Food Market Size To Worth USD 4.87 Billion By 2033 | CAGR Of 13.12%
-
Innocan1 week agoInnocan Pharma Announces Closing of Private Placement and Grant of Stock Options
-
Indivior4 days agoIndivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
